[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
[2]EYCK BM,LANSCHOT JJB,HULSHOF MCCM,et al.Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer:The randomized controlled CROSS trial [J].J Clin Oncol,2021,39(18):1995-2004.
[3]ANDO N,KATO H,IGAKI H,et al.A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus(JCOG9907) [J].Ann Surg Oncol,2012,19(1):68-74.
[4]NAKAMURA K,KATO K,IGAKI H,et al.Three-arm phase Ⅲ trial comparing cisplatin plus 5-FU(CF) versus docetaxel,cisplatin plus 5-FU(DCF) versus radiotherapy with CF(CF-RT) as preoperative therapy for locally advanced esophageal cancer(JCOG1109,NExT study)[J].Japanese Journal of Clinical Oncology,2013,43(7):752-755.
[5]王绿化,黄镜,韩泳涛,等.2022年中国临床肿瘤学会食管癌诊疗指南[M].北京:人民卫生出版社,2022:48. WANG LH,HUANG J,HAN YT,et al.The Chinese society of clinical oncology guidelines for the diagnosis and treatment of esophageal cancer in 2022[M].Beijing:People’s Medical Publishing House,2022:48.
[6]TANG H,WANG H,FANG Y,et al.Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma:a prospective multicenter randomized clinical trial [J].Annals of Oncology,2023,34(2):163-172.
[7]SCHOBER P,MASCHA EJ,VETTER TR,et al.Statistics from A(Agreement) to Z(Z score):A guide to interpreting common measures of association,agreement,diagnostic accuracy,effect Size,heterogeneity,and reliability in medical research [J].Anesthesia & Analgesia,2021,133(6):1633-1641.
[8]BANCEWICZ J,CLARK PI,SMITH DB,et al.Surgical resection with or without preoperative chemotherapy in oesophageal cancer:a randomised controlled trial[J].The Lancet,2002,359(9319):1727-1733.
[9]YANG H,LIU H,CHEN Y,et al.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus(NEOCRTEC5010):A phase Ⅲ multicenter,randomized,open-label clinical trial[J].J Clin Oncol,2018,36(27):2796-2803.
[10]ALLUM WH,STENNING SP,BANCEWICZ J,et al.Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer [J].J Clin Oncol,2009,27(30):5062-5067.
[11]STAHL M,WALZ MK,STUSCHKE M,et al.Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction [J].J Clin Oncol,2009,27(6):851-856.
[12]BURMEISTER BH,THOMAS JM,BURMEISTER EA,et al.Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial[J].European Journal of Cancer,2011,47(3):354-360.
[13]KLEVEBRO F,VON DOBELN GA,WANG N,et al.A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J].Annals of Oncology,2016,27(4):660-667.
[14]AL-SUKHNI E,GABRIEL E,ATTWOOD K,et al.No survival difference with neoadjuvant chemoradiotherapy compared with chemotherapy in resectable esophageal and gastroesophageal junction adenocarcinoma:results from the National Cancer Data Base[J].Journal of the American College of Surgeons,2016,223(6):784-792.e1.
[15]CHAN KKW,SALUJA R,DELOS SANTOS K,et al.Neoadjuvant treatments for locally advanced,resectable esophageal cancer:A network meta-analysis [J].International Journal of Cancer,2018,143(2):430-437.
[16]ZHANG G,ZHANG C,SUN N,et al.Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma:a propensity score-matched study from the National Cancer Center in China[J].Journal of Cancer Research and Clinical Oncology,2022,148(4):943-954.
[17]OKAMURA A,WATANABE M,OKUI J,et al.Neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy for patients with esophageal squamous cell carcinoma:real-world data comparison from a Japanese nationwide study[J].Annals of Surgical Oncology,2023,30(9):5885-5894.
[18]DENG HY,WANG WP,WANG YC,et al.Neoadjuvant chemoradiotherapy or chemotherapy?A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer[J].European Journal of Cardio-Thoracic Surgery,2017,51(3):421-431.
[19]YANG Y,LI H,CHEN X,et al.Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma[J].Thoracic Cancer,2023,14(7):700-708.
[20]AKIHIKO OKAMURA,MASAYUKI WATANABE,JUN OKUI,et al.Neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy for patients with esophageal squamous cell carcinoma:Real-world data comparison from a Japanese nationwide study[J].Ann Surg Oncol,2023,30(9):5885-5894.
[21]VON DOBELN GA,KLEVEBRO F,JACOBSEN AB,et al.Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction:long-term results of a randomized clinical trial[J].Diseases of the Esophagus,2019,32(2):doy078.
[22]LI Z,LIU J,ZHANG M,et al.A phase II study of neoadjuvant immunotherapy combined with chemotherapy(camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer(NICE study):Interim results [J].J Clin Oncol,2021,39(15_suppl):4060.
[23]WU Z,ZHENG Q,CHEN H,et al.Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma[J].Journal of Thoracic Disease,2021,13(6):3518.
[24]LIU J,LI J,LIN W,et al.Neoadjuvant camrelizumab plus chemotherapy for resectable,locally advanced esophageal squamous cell carcinoma(NIC-ESCC2019):a multicenter,phase 2 study[J].International Journal of Cancer,2022,151(1):128-137.
[25]LI C,ZHAO S,ZHENG Y,et al.Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma(PALACE-1)[J].European Journal of Cancer,2021,144:232-241.
[26]VAN DEN ENDE T,DE CLERCQ NC,VAN BERGE HENEGOUWEN MI,et al.Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma:a single-arm phase II feasibility trial(PERFECT)[J].Clinical Cancer Research,2021,27(12):3351-3359.